Douglas Kyle Hogarth to Treatment Outcome
This is a "connection" page, showing publications Douglas Kyle Hogarth has written about Treatment Outcome.
Connection Strength
0.288
-
Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with Alpha-1 antitrypsin deficiency (EMPROVE). Respir Med. 2024 Apr; 224:107565.
Score: 0.099
-
Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study. Thorac Cancer. 2022 04; 13(7):1014-1020.
Score: 0.022
-
Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update. Respiration. 2021; 100(10):969-978.
Score: 0.021
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.020
-
Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019 12 01; 200(11):1354-1362.
Score: 0.019
-
Intrabronchial Valves for Air Leaks After Lobectomy, Segmentectomy, and Lung Volume Reduction Surgery. Lung. 2019 10; 197(5):627-633.
Score: 0.018
-
A successful bronchial thermoplasty procedure in a "very severe" asthma patient with rare complications: a case report. J Asthma. 2019 Sep; 56(9):1004-1007.
Score: 0.017
-
Bronchial Thermoplasty: A Decade of Experience: State of the Art. J Allergy Clin Immunol Pract. 2019 01; 7(1):71-80.
Score: 0.017
-
Effect of Endoscopic Bronchial Ultrasound on Outcomes for Stage I Non-Small-Cell Lung Cancer Patients Receiving Hypofractionated Radiotherapy. Clin Lung Cancer. 2018 03; 19(2):e227-e233.
Score: 0.016
-
Mediastinal granuloma: a rare cause of dysphagia. BMJ Case Rep. 2016 Jun 14; 2016.
Score: 0.015
-
A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J. 2015 Sep; 46(3):651-62.
Score: 0.013
-
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18; 31(1):46-54.
Score: 0.013